[HTML][HTML] Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
…, K Schultheis, TRF Smith, SJ Ramos, T McMullan… - …, 2021 - thelancet.com
Background A vaccine against SARS-CoV-2 is of high urgency. Here the safety and
immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of …
immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of …
Intradermal SynCon® Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers
…, D Amante, T Racine, T McMullan… - The Journal of …, 2019 - academic.oup.com
Background Nonlive vaccine approaches that are simple to deliver and stable at room
temperature or 2–8C could be advantageous in controlling future Ebola virus (EBOV) outbreaks. …
temperature or 2–8C could be advantageous in controlling future Ebola virus (EBOV) outbreaks. …
[HTML][HTML] INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
…, K Schultheis, M Purwar, E Reuschel, T McMullan… - npj Vaccines, 2021 - nature.com
Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC)
associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced …
associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced …
SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial
…, MP Morrow, P Pezzoli, T McMullan… - The Journal of …, 2022 - academic.oup.com
Background Additional severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines that are safe and effective as primary vaccines and boosters remain urgently needed …
vaccines that are safe and effective as primary vaccines and boosters remain urgently needed …
[HTML][HTML] Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL …
…, J Pawlicki, AJ Sylvester, T McMullan… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Background Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’tumor
associated antigen due to its expression in a vast number of cancers. We …
associated antigen due to its expression in a vast number of cancers. We …
[HTML][HTML] CD8+ T cells impact rising PSA in biochemically relapsed cancer patients using immunotherapy targeting tumor-associated antigens
ND Shore, MP Morrow, T McMullan, KA Kraynyak… - Molecular Therapy, 2020 - cell.com
The management of men with prostate cancer (PCa) with biochemical recurrence following
local definitive therapy remains controversial. Early use of androgen deprivation therapy (…
local definitive therapy remains controversial. Early use of androgen deprivation therapy (…
INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM …
…, I Lowy, J Boyer, K Kraynyak, MP Morrow, T McMullan… - 2020 - ascopubs.org
2514 Background: Novel T cell-enabling therapies, in combination with checkpoint inhibition,
may improve OS in GBM. INO-5401 (synthetic DNA plasmids encoding for hTERT, WT-1 …
may improve OS in GBM. INO-5401 (synthetic DNA plasmids encoding for hTERT, WT-1 …
Abstract CT114: INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab (REGN2810) in newly-diagnosed glioblastoma (GBM) …
…, I Lowy, M Fury, M Morrow, K Kraynyak, T McMullan… - Cancer Research, 2019 - AACR
Despite advances in therapy, glioblastoma (GBM) remains one of the most deadly cancers,
with five-year survival under 5%. Newer immunotherapies hold promise in the treatment of …
with five-year survival under 5%. Newer immunotherapies hold promise in the treatment of …
[HTML][HTML] Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias.
…, G Martinelli, V Kelly, N Besson, T McMullan… - Blood, 2010 - Elsevier
Abstract 3434 Bosutinib (SKI-606) is a dual Src/Abl tyrosine kinase inhibitor (TKI) with minimal
inhibitory activity against PDGFR or c-kit. Previous reports of this open-label, phase 1/2 …
inhibitory activity against PDGFR or c-kit. Previous reports of this open-label, phase 1/2 …
[HTML][HTML] Bosutinib as third-line treatment for chronic phase chronic myeloid leukemia following failure of second-line therapy with dasatinib or nilotinib
…, M Zanichelli, V Kelly, N Besson, T McMullan… - Blood, 2010 - Elsevier
Abstract 892 Bosutinib (SKI-606) is an orally available, dual Src/Abl tyrosine kinase inhibitor
(TKI) with minimal inhibitory activity against PDGFR or c-kit. This open-label, phase 1/2 …
(TKI) with minimal inhibitory activity against PDGFR or c-kit. This open-label, phase 1/2 …